StockData
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc. (CLRB) stock

CLRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.92−0.09 (-8.88%)

Close on Nov 17, 2026Market cap $8.70MP/E –Yield –

Cellectar Biosciences total assets

Total assets on the balance sheet at the end of each period.

Cellectar Biosciences's total assets was $36.64M at Jun 30, 2026. For fiscal 2025 it was $14.98M, down 41.2% from the year before. Over ten years it grew 7.0% a year on average. The highest annual figure on record is $58.66M in fiscal 2020.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$14.98M-41.2%
FY2024Dec 31, 2024$25.47M+111.0%
FY2023Dec 31, 2023$12.08M-44.1%
FY2022Dec 31, 2022$21.59M-42.0%
FY2021Dec 31, 2021$37.20M-36.6%
FY2020Dec 31, 2020$58.66M+378.8%
FY2019Dec 31, 2019$12.25M-18.6%
FY2018Dec 31, 2018$15.05M+17.0%
FY2017Dec 31, 2017$12.87M-16.0%
FY2016Dec 31, 2016$15.32M+101.7%
FY2015Dec 31, 2015$7.60M-43.4%
FY2014Dec 31, 2014$13.42M+96.9%
FY2013Dec 31, 2013$6.82M-40.6%
FY2012Dec 31, 2012$11.48M+8.7%
FY2011Dec 31, 2011$10.56M+120.0%
FY2010Dec 31, 2010$4.80M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$36.64M+167.5%
Q1 FY2026Mar 31, 2026$11.12M-30.7%
Q4 FY2025Dec 31, 2025$14.98M-41.2%
Q3 FY2025Sep 30, 2025$14.63M-60.8%
Q2 FY2025Jun 30, 2025$13.70M-53.4%
Q1 FY2025Mar 31, 2025$16.04M-62.6%
Q4 FY2024Dec 31, 2024$25.47M+111.0%
Q3 FY2024Sep 30, 2024$37.29M+73.0%
Q2 FY2024Jun 30, 2024$29.38M+351.4%
Q1 FY2024Mar 31, 2024$42.91M+189.2%
Q4 FY2023Dec 31, 2023$12.08M-44.1%
Q3 FY2023Sep 30, 2023$21.55M+11.5%
Q2 FY2023Jun 30, 2023$6.51M-74.9%
Q1 FY2023Mar 31, 2023$14.84M-53.6%
Q4 FY2022Dec 31, 2022$21.59M-42.0%
Q3 FY2022Sep 30, 2022$19.32M-53.9%
Q2 FY2022Jun 30, 2022$25.89M-45.8%
Q1 FY2022Mar 31, 2022$31.99M-41.9%
Q4 FY2021Dec 31, 2021$37.20M-36.6%
Q3 FY2021Sep 30, 2021$41.95M+102.7%
Q2 FY2021Jun 30, 2021$47.74M+100.1%
Q1 FY2021Mar 31, 2021$55.06M+533.7%
Q4 FY2020Dec 31, 2020$58.66M+378.8%
Q3 FY2020Sep 30, 2020$20.70M+32.2%
Q2 FY2020Jun 30, 2020$23.85M+24.6%
Q1 FY2020Mar 31, 2020$8.69M-30.8%
Q4 FY2019Dec 31, 2019$12.25M-18.6%
Q3 FY2019Sep 30, 2019$15.66M-19.9%
Q2 FY2019Jun 30, 2019$19.14M+173.5%
Q1 FY2019Mar 31, 2019$12.55M+31.2%
Q4 FY2018Dec 31, 2018$15.05M+17.0%
Q3 FY2018Sep 30, 2018$19.54M+98.0%
Q2 FY2018Jun 30, 2018$7.00M-44.5%
Q1 FY2018Mar 31, 2018$9.56M-37.5%
Q4 FY2017Dec 31, 2017$12.87M-16.0%
Q3 FY2017Sep 30, 2017$9.87M+6.2%
Q2 FY2017Jun 30, 2017$12.60M–
Q1 FY2017Mar 31, 2017$15.30M–
Q4 FY2016Dec 31, 2016$15.32M–
Q3 FY2016Sep 30, 2016$9.30M–

More Cellectar Biosciences figures

See a number that looks wrong?